Shots: The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized […]readmore
Tags : Decision
Shots: The US FDA has extended the PDUFA date for its review of risdiplam’s NDA with the expected decision by Aug 24, 2020. The extension is based on the submission […]readmore
Shots: The NAVIFY Tumor Board 2.0 with medical imaging capabilities brings a personalized treatment in patients with cancer with its initial availability in the US & Canada The tumor board […]readmore